Strength of UK Life Sciences confirmed at Future of Healthcare Investor ForumLondon Stock Exchange Group hosts its fourth annual Future of Healthcare Investor Forum today to showcase the continued growth of the UK life sciences sector and its significance to the UK and wider global economy.

To mark the occasion, Nikhil Rathi, CEO, London Stock Exchange Plc welcomed Robert Jenrick MP, Exchequer Secretary to the Treasury, to open the London market alongside Sarah Haywood, CEO, MedCity and Steve Bates, CEO, BioIndustry Association. They were joined by conference sponsors, Consilium Strategic Communications, J.P. Morgan, Manches, Numis, Penningtons, PwC and partners BioIndustry Association (BIA) and One Nucleus.

Life sciences & healthcare key UK statistics:• Approximately £2.4 billion was raised in life sciences IPOs and further offerings on London Stock Exchange in 2017, +20% compared to 2016 • Funding was driven by UK listed life sciences companies returning to the market to raise follow on capital; over £2.1 billion was raised in follow on capital in 2017, a six-fold increase compared to 2016• The UK public markets continue to support innovation: o In March 2017, US-based fund BioPharma Credit became the first London listed fund to specialise in debt financing for the life sciences sector. o BioPharma Credit raised £611 million on the Specialist Fund Segment of the Main Market, highlighting the global investor interest in UK life sciences.o In February 2017 Arix Bioscience, a company focusing on generating value from health and life sciences, raised £113 million on the Main Market.o The float of Novacyt SA, a French diagnostics group, on AIM in November 2017, highlighted the continued appetite for international life sciences companies to list in London.• 120 life sciences companies are currently listed on London Stock Exchange, with a combined market capitalisation over £220 billion.

The UK-listed healthcare sector continues to be a source of outperformance for investors:• Over three years the FTSE AIM Healthcare index has continued to outperform wider indexes to end 2017 up 82%, compared to an increase of 50% for the FTSE AIM All Share index• In 2017 alone, the FTSE AIM Healthcare index increased by 39%, compared to 24% for the FTSE AIM All Share index

Nikhil Rathi, CEO, London Stock Exchange Plc:“London Stock Exchange has supported UK and international life sciences companies in raising over £2 billion in follow on capital in 2017 alone. This is testament to the London market’s long-term attractiveness to a broad range of life sciences companies, giving them access to a deep liquid pool of global growth capital. “We are proud to gather today UK Government, the life sciences industry and investors, to champion the UK’s unique ecosystem and support long term life science innovation, fundraising and investment in the UK and the rest of the world.”